Wheat in skin care
Conclusion
Can the presence of wheat hydrolysates in personal care products adversely affect a patient with celiac sprue or wheat sensitivity? The short answer appears to be “yes.” Given the use of hydrolyzed wheat protein in various skin care products, it is important that consumers who have celiac disease or sensitivity to wheat be advised to avoid skin care formulations with such active ingredients. On the positive side of the wheat ledger, there are some indications (albeit in very limited research) that the plant protein may impart beneficial health effects. Much more research is necessary to delineate the full impact of wheat on skin health.
I thank my dermatologist colleague Sharon E. Jacob, MD, at the University of Miami, for suggesting this topic.
References
2. Iran J Med Sci. 2016 May;41(3 Suppl):S54.
3. Contact Dermatitis. 2007 Feb;56(2):119-20.
4. Ann Dermatol Venereol. 2010 Apr;137(4):281-4.
5. Allergy. 1998 Nov;53(11):1078-82.
6. J Drugs Dermatol. 2013 Sep;12(9 Suppl):s133-6.
7. Pak J Pharm Sci. 2008 Jan;21(1):45-50.
8. Cancer Biother Radiopharm. 2008 Aug;23(4):477-82.
9. Nutr Cancer. 2009;61(6):891-9.
10. Ann N Y Acad Sci. 2005 Jun;1051:529-42.
11. Eur Ann Allergy Clin Immunol. 2006 Apr;38(4):126-30.
12. Nutrients. 2015 Sep 15;7(9):7798-805.
13. Allergy. 2014 Oct;69(10):1405-11.
14. Yakugaku Zasshi. 2014;134(1):33-8.
15. Intern Med. 2014;53(2):151-4.
16. Dermatitis. 2012 Sep-Oct;23(5):220-1.
17. Acta Medica (Hradec Kralove). 2011;54(4):157-62.
18. Contact Dermatitis. 2006 May;54(5):283-9.
19. Contact Dermatitis. 2013 Jun;68(6):379-80.
Dr. Baumann is chief executive officer of the Baumann Cosmetic & Research Institute in the Design District in Miami. She founded the Cosmetic Dermatology Center at the University of Miami in 1997. Dr. Baumann wrote the textbook “Cosmetic Dermatology: Principles and Practice” (New York: McGraw-Hill, 2002), and a book for consumers, “The Skin Type Solution” (New York: Bantam Dell, 2006). Her latest book, “Cosmeceuticals and Cosmetic Ingredients,” was published in November 2014. Dr. Baumann has received funding for clinical grants from Allergan, Aveeno, Avon Products, Evolus, Galderma, GlaxoSmithKline, Kythera Biopharmaceuticals, Mary Kay, Medicis Pharmaceuticals, Neutrogena, Philosophy, Topix Pharmaceuticals, and Unilever. Dr. Baumann also developed and owns the Baumann Skin Type Solution skin typing systems and related products.
